This last problem has been overcome by introducing CD38 multiepitope antibodies that permit, by binding to sites that are different from the one occupied by the drug, to still recognize MM PCs even during treatment with Anti-CD38 monoclonal antibodies (67). Here, CD38 is linked to Miyoshi myopathy.